Quantum Leap provides update on I-SPY 2 breast cancer trial

Quantum Leap Healthcare Collaborative provided an update on the overall progress of the Phase II I-SPY 2 trial evaluating neoadjuvant treatments for breast cancer in patients at high risk for early recurrence.

Quantum Leap said thus far, I-SPY 2 has enrolled over 1,300 patients. By year end, 17 drugs or drug candidates will have entered the trial and 12 will have completed evaluation. The non-profit said seven products have already graduated from the trial, two have received accelerated approval and one has received breakthrough therapy designation...